ClinicalTrials.gg
Enrolling by invitationNCT07937592Updated Nov 16, 2026

Study the Mechanism and Effectiveness of Probiotics on Atopic Dermatitis

An interventional study of Probiotic 2 × 10^8 and Placebo capsule in Atopic Dermatitis and Eczema, sponsored by National Cheng-Kung University Hospital. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by National Cheng-Kung University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Oct 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies in Dermatitis, Atopic with a site in Taiwan — 10 open to participants now, 21 under way, 8 of them phase 3. Dermatitis, Atopic · Taiwan.

Planned enrollment
43rd of 60
90 · median 290
Started
2026
with 4 others
No phase
9 of 70
4 open now
Primary completion
2027-12
later than 12 of 20 live
Registered
70th of 70
by date

Among the 70 studies in Dermatitis, Atopic with a site in Taiwan, this one is the 43rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2026, is one of 9 with no phase, reaches primary completion later than 12 of the 20 other live ones, and was the 70th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

10 of the 70 studies in Dermatitis, Atopic with a site in Taiwan are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Dermatitis, Atopic with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether probiotics isolated from breast milk and healthy infant feces can reduce the severity of atopic dermatitis (eczema) in children aged 3 to 18 years with moderate-to-severe disease. The main questions it aims to answer are:

  • Does taking the probiotic capsule twice daily for 12 weeks reduce eczema severity, measured by the EASI SCORAD?
  • Does the probiotic improve quality of life, blood markers of allergic inflammation (IgE, histamine, IL-31, T-cell subsets), and gut microbiota composition? Researchers will compare the probiotic to a placebo capsule that looks the same but contains no probiotic bacteria.

Participants will:

  • Take one capsule twice daily for 12 weeks, in addition to their usual atopic dermatitis treatment
  • Complete the PO-SCORAD and a quality-of-life questionnaire at baseline and weeks 2, 4, 8 and 12
  • Provide stool samples at baseline and weeks 4 and 12, and a 10 mL blood sample at baseline and week 12.
Read the detailed description

Detailed Description Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder that typically manifests in infancy and may persist into adulthood, with an estimated prevalence of approximately 21% among Taiwanese children aged 6 months to 18 years. Its pathogenesis is multifactorial, involving genetic susceptibility, epidermal barrier dysfunction, and immune dysregulation. Type 2 cytokines, including IL-4, IL-5, IL-13, and IL-31, suppress keratinocyte barrier proteins and lipids, promote IgE production, and activate eosinophils and mast cells. IL-4 and IL-13 also act directly on itch-sensory neurons and potentiate IL-31 signaling. IL-31, often termed the "itch cytokine", further induces Th1-associated mediators (IFN-γ, TNF-α, and IL-17) via the JAK/STAT pathway, thereby contributing to disease chronicity.

Rationale: Accumulating evidence implicates intestinal dysbiosis in AD pathogenesis through the gut-skin axis, with depletion of commensal Lactobacillus and Bifidobacterium consistently associated with disease onset and exacerbation. In a prospective healthy full-term birth cohort (n = 338), the investigators observed that infants who developed AD by 12 months of age exhibited significantly lower fecal abundance of Bifidobacterium, particularly Bifidobacterium longum, at 16 weeks of age. A total of 257 Lactobacillus and Bifidobacterium isolates were subsequently obtained from human breast milk and healthy infant feces and screened in vitro for acid and bile tolerance, immunomodulatory activity, and attenuation of LPS-induced cytokine production in peripheral blood mononuclear cells. Two lead candidates, B. longum and B. bifidum [TBC: final product strains], ameliorated skin lesions, improved skin hydration, and reduced transepidermal water loss in a diet-induced HR-1 hairless mouse model of AD. However, the clinical efficacy and immunological mechanisms of these strains in children remain to be established.

Study design and intervention: This is a single-center, prospective, randomized, double-blind, placebo-controlled, parallel-group trial conducted at National Cheng Kung University Hospital, Tainan, Taiwan. Ninety children aged 3 to 18 years with moderate-to-severe AD receiving standard care are randomized in a 2:1 ratio to probiotic (n = 60) or placebo (n = 30). The investigational product is manufactured in a GMP- and FSSC 22000-certified facility (New Bellus Enterprises Co., Ltd.). Each capsule contains 2 × 10\^9 CFU [TBC: per gram or per capsule]; the placebo capsule contains excipient only and is identical in appearance. Participants take one capsule orally twice daily for 12 weeks as an adjunct to standard therapy, which continues at the discretion of the attending physician. For young children or those unable to swallow capsules, the contents may be dispersed in milk or juice at no more than 40 °C.

Assessments: Disease severity is assessed with the Patient-Oriented SCORAD (PO-SCORAD), and health-related quality of life with [TBC: instrument], at randomization and at weeks 2, 4, 8, and 12. Fecal samples are collected at baseline and at weeks 4 and 12, stored frozen, and analyzed by 16S rRNA gene (V3-V4) amplicon sequencing to characterize gut microbial diversity and taxonomic composition. Peripheral blood (10 mL) is obtained at baseline and week 12 for T-cell subset profiling by flow cytometry and for quantification of serum total IgE, histamine, and IL-31 by ELISA. Participants who experience clinical deterioration are withdrawn from the study and managed with alternative therapy.

Objectives: The study aims to determine the clinical efficacy of the candidate probiotics in reducing AD severity and pruritus, and to elucidate whether clinical response is associated with restoration of gut microbial homeostasis and modulation of the type 2/IL-31 inflammatory axis.

03

Conditions studied

  • Atopic Dermatitis
  • Eczema

Keywords

  • probiotics
  • Bifidobacterium
  • gut microbiota
  • gut-skin axis
  • pediatric
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 3 to 18 years
  • Diagnosis of atopic dermatitis with moderate-to-severe disease, defined as an Eczema Area and Severity Index (EASI) score > 7 at screening
  • Receiving regular atopic dermatitis treatment at National Cheng Kung University Hospital
  • Written from the participant's legal representative, with assent from participants aged 7 years and older

Exclusion criteria

Exclusion Criteria:

  • Skin disease other than atopic dermatitis
  • Current or planned treatment with a biologic agent (e.g., dupilumab, an anti-IL-4Rα antibody)
  • Current or planned treatment with an oral small-molecule (e.g., upadacitinib)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Probiotic 2*10^8

    One probiotic(2\*10\^8) twice daily for 12 weeks, in addition to regular atopic dermatitis treatment.

    Dietary Supplement: Probiotic 2 × 10^8

  • Experimental
    Probiotic 2*10^10

    One probiotic(2\*10\^10) twice daily for 12 weeks, in addition to regular atopic dermatitis treatment.

    Dietary Supplement: Probiotic 2 × 10^10

  • Placebo comparator
    Placebo

    One identical-appearing placebo capsule twice daily for 12 weeks, in addition to regular atopic dermatitis treatment.

    Other: Placebo capsule

Interventions

  • Dietary supplementProbiotic 2 × 10^8

    Capsule containing 2 × 10\^8 CFU \[TBC: per gram or per capsule\] of Bifidobacterium longum and Bifidobacterium bifidum \[TBC: final strains\] isolated from breast milk and healthy infant feces. Taken orally twice daily for 12 weeks; contents may be mixed with milk or juice at no more than 40 °C.

  • OtherPlacebo capsule

    Capsule of identical appearance containing excipient only, without probiotic bacteria. Taken orally twice daily for 12 weeks.

  • Dietary supplementProbiotic 2 × 10^10

    Capsule containing 2 × 10\^10 CFU \[TBC: per gram or per capsule\] of Bifidobacterium longum and Bifidobacterium bifidum \[TBC: final strains\] isolated from breast milk and healthy infant feces. Taken orally twice daily for 12 weeks; contents may be mixed with milk or juice at no more than 40 °C.

06

What researchers measure

Primary outcomes

  1. Change in Eczema Area and Severity Index (EASI) score from baseline to week 12

    Clinician-assessed EASI. Score range 0-72; higher scores indicate more severe disease.

    Time frame: Baseline, week4, week8, week 12

  2. Change in gut microbial

    Relative abundance (%) of the gut microbial from 16S rRNA gene (V1-V9) sequencing of stool.

    Time frame: Baseline, weeks 4 and 12

  3. Change in PO-SCORAD

    Patient-Oriented SCORAD completed by the participant or primary caregiver (range 0-103; higher = worse).

    Time frame: Baseline, week4, week8, week 12

  4. Change in quality of life

    For different ages, IDQOL, CDLQI, or DLQI, completed by the participant or primary caregiver.(range:0-30)

    Time frame: Baseline, week4, week8, week 12

  5. Change in serum total IgE

    Serum total IgE concentration (IU/mL).

    Time frame: Baseline and week 12

  6. Change in serum histamine

    Serum histamine concentration measured by ELISA (ng/mL).

    Time frame: Baseline and week 12

  7. Change in serum IL-4

    Serum interleukin-4 concentration measured by ELISA (pg/mL).

    Time frame: Baseline and week 12

  8. Change in serum IL-13

    Serum interleukin-13 concentration measured by ELISA (pg/mL).

    Time frame: Baseline and week 12

  9. Change in serum IL-31

    Serum interleukin-31 concentration measured by ELISA (pg/mL).

    Time frame: Baseline and week 12

  10. Change in white blood cell count

    Total white blood cell count from complete blood count (cells/μL).

    Time frame: Baseline and week 12

  11. Change in absolute lymphocyte count

    Absolute lymphocyte count (cells/μL).

    Time frame: Baseline and week 12

  12. Change in absolute CD3+ T-cell count

    Absolute CD3+ T-cell count measured by flow cytometry (cells/μL).

    Time frame: Baseline and week 12

  13. Change in absolute CD4+ helper T-cell count

    Absolute CD4+ T-cell count measured by flow cytometry (cells/μL).

    Time frame: Baseline and week 12

  14. Change in absolute CD8+ suppressor/cytotoxic T-cell count

    Absolute CD8+ T-cell count measured by flow cytometry (cells/μL).

    Time frame: Baseline and week 12

  15. Change in CD4+/CD8+ T-cell ratio

    Ratio of CD4+ to CD8+ T cells measured by flow cytometry (ratio, unitless).

    Time frame: Baseline and week 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The informed consent does not cover the sharing of individual participant data outside the study team. De-identified data are stored at National Cheng Kung University Hospital until 2050, and aggregate results will be published in medical conferences and journals.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 113 non-industry interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 18 months is close to that.

Counting every sponsor, half of 182 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2026
First posted
Nov 16, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937592
Responsible party
Yao-Jong Yang (Professor, National Cheng-Kung University Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Jun 30, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Yao-Jong Yang, MD, PhD
principal investigator · National Cheng-Kung University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion